NYSEAMERICAN:MYO Myomo Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Myomo, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.66 -0.02 (-1.19%) (As of 07/1/2022 05:43 PM ET) Add Compare Share Today's Range$1.64▼$1.7550-Day Range N/A52-Week Range$1.61▼$14.35Volume27,410 shsAverage Volume106,107 shsMarket Capitalization$11.42 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Myomo Stock Forecast (MarketRank)Analyst RatingBuy3.00 Rating ScoreUpside/Downside713.3% Upside$13.50 Price TargetShort InterestHealthy0.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.31) to ($1.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.60 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMyomo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.50, Myomo has a forecasted upside of 713.3% from its current price of $1.66.Amount of Analyst CoverageMyomo has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.29% of the float of Myomo has been sold short.Short Interest Ratio / Days to CoverMyomo has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Myomo has recently increased by 11.31%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMyomo does not currently pay a dividend.Dividend GrowthMyomo does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MYO. Previous Next 1.5 News and Social Media Coverage News SentimentMyomo has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myomo insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Myomo is held by insiders.Percentage Held by InstitutionsOnly 38.96% of the stock of Myomo is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Myomo are expected to grow in the coming year, from ($1.31) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myomo is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myomo is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyomo has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myomo and its competitors with MarketBeat's FREE daily newsletter. Email Address About Myomo (NYSEAMERICAN:MYO)Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.Read More MYO Stock News HeadlinesJune 16, 2022 | benzinga.comMyomo's Return On Capital Employed Insights - Benzinga - BenzingaJune 15, 2022 | finance.yahoo.comMilitary Exoskeleton Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027) - Yahoo FinanceJune 9, 2022 | finance.yahoo.comMyomo To Present at the Sidoti Summer Small Cap Virtual Investor ConferenceJune 9, 2022 | businesswire.comGlobal Powered Exoskeleton Market (2022 to 2028) - Featuring Bionic Power, Cyberdyne and Daewoo Among Others - ResearchAndMarkets.com - Business WireMay 11, 2022 | seekingalpha.comMyomo, Inc. (MYO) CEO Paul Gudonis on Q1 2022 Results - Earnings Call TranscriptMay 11, 2022 | businesswire.comMyomo Reports First Quarter 2022 Financial Results - Business WireMay 11, 2022 | finance.yahoo.comMyomo Reports First Quarter 2022 Financial ResultsMay 10, 2022 | benzinga.comMyomo Earnings Preview - Benzinga - BenzingaMay 9, 2022 | nasdaq.comBlink Charging (BLNK) Reports Q1 Loss, Tops Revenue Estimates - NasdaqMay 9, 2022 | nasdaq.comICU Medical (ICUI) Surpasses Q1 Earnings Estimates - NasdaqMay 4, 2022 | businesswire.comMyomo to Report First Quarter Financial Results on May 11, 2022 - Business WireMay 4, 2022 | finance.yahoo.comMyomo to Report First Quarter Financial Results on May 11, 2022April 5, 2022 | businesswire.comMyomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee - Business WireApril 4, 2022 | streetinsider.comMyomo (MYO) Receives Partial Payment of Technology License Fee, Reports Progress on JV in China - StreetInsider.comApril 4, 2022 | seekingalpha.comMyomo receives partial payment for technology license fee from China JV - Seeking AlphaApril 4, 2022 | finance.yahoo.comMyomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License FeeMarch 10, 2022 | benzinga.comMid-Day Market Update: Nasdaq Drops 250 Points; CrowdStrike Shares Gain On Upbeat Earnings - Benzinga - BenzingaMarch 10, 2022 | businesswire.comMyomo Reports Fourth Quarter and Full Year 2021 Financial Results - Business WireMarch 9, 2022 | seekingalpha.comMyomo, Inc. (MYO) CEO Paul Gudonis on Q4 2021 Results - Earnings Call Transcript - Seeking AlphaMarch 9, 2022 | benzinga.comMyomo: Q4 Earnings Insights - Benzinga - BenzingaMarch 9, 2022 | streetinsider.comMyomo To Participate in Two March Investor Conferences - StreetInsider.comMarch 9, 2022 | finance.yahoo.comMyomo Reports Fourth Quarter and Full Year 2021 Financial Results - Yahoo FinanceMarch 9, 2022 | finance.yahoo.comMyomo Reports Fourth Quarter and Full Year 2021 Financial ResultsMarch 9, 2022 | finance.yahoo.comMyomo To Participate in Two March Investor ConferencesMarch 8, 2022 | seekingalpha.comMyomo Q4 2021 Earnings PreviewSee More Headlines Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:MYO CUSIPN/A CIK1369290 Webmyomo.com Phone(617) 996-9058FaxN/AEmployees87Year FoundedN/ACompany Calendar Last Earnings5/11/2022Today7/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$13.50 High Stock Price Forecast$17.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+713.3%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10.37 million Net Margins-66.45% Pretax Margin-65.56% Return on Equity-74.05% Return on Assets-55.85% Debt Debt-to-Equity RatioN/A Current Ratio3.57 Quick Ratio3.35 Sales & Book Value Annual Sales$13.86 million Price / Sales0.82 Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / Book0.74Miscellaneous Outstanding Shares6,880,000Free Float6,751,000Market Cap$11.42 million OptionableNot Optionable Beta1.14 Myomo Frequently Asked Questions Should I buy or sell Myomo stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Myomo stock. View analyst ratings for Myomo or view top-rated stocks. What is Myomo's stock price forecast for 2022? 3 Wall Street research analysts have issued twelve-month price targets for Myomo's stock. Their MYO stock forecasts range from $10.00 to $17.00. On average, they anticipate Myomo's share price to reach $13.50 in the next year. This suggests a possible upside of 713.3% from the stock's current price. View analysts' price targets for Myomo or view top-rated stocks among Wall Street analysts. Are investors shorting Myomo? Myomo saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 16,800 shares, an increase of 43.6% from the May 15th total of 11,700 shares. Based on an average trading volume of 45,700 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.3% of the shares of the stock are sold short. View Myomo's Short Interest. How were Myomo's earnings last quarter? Myomo, Inc. (NYSEAMERICAN:MYO) posted its quarterly earnings data on Wednesday, May, 11th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.13. Myomo had a negative trailing twelve-month return on equity of 74.05% and a negative net margin of 66.45%. View Myomo's earnings history. Who are Myomo's key executives? Myomo's management team includes the following people: Mr. Paul R. Gudonis, Chairman, Pres & CEO (Age 67, Pay $459.18k)Mr. David A. Henry, Chief Financial Officer (Age 61, Pay $369.01k)Mr. Micah J. Mitchell, Chief Commercial Officer (Age 46, Pay $317.39k)Dr. Harry Kovelman M.D., Chief Medical Officer (Age 63) Who are some of Myomo's key competitors? Some companies that are related to Myomo include Invacare (IVC), Nutriband (NTRB), Eargo (EAR), Predictive Oncology (POAI), Surgalign (SRGA), NanoVibronix (NAOV), Bone Biologics (BBLG), Ortho Regenerative Technologies (ORTIF), Bionik Laboratories (BNKL), Advanced Biomedical Technologies (ABMT), Allied Healthcare Products (AHPI), Avitar (AVTI), CollPlant Biotechnologies (CLGN), Pathfinder Cell Therapy (PFND) and PC Group (PCGR). View all of MYO's competitors. What other stocks do shareholders of Myomo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myomo investors own include Genocea Biosciences (GNCA), Agile Therapeutics (AGRX), Sarepta Therapeutics (SRPT), Aclaris Therapeutics (ACRS), Remark (MARK), Protalix BioTherapeutics (PLX), Synergy Pharmaceuticals (SGYP), VBI Vaccines (VBIV), Athersys (ATHX) and Anavex Life Sciences (AVXL). What is Myomo's stock symbol? Myomo trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MYO." How do I buy shares of Myomo? Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Myomo's stock price today? One share of MYO stock can currently be purchased for approximately $1.66. How much money does Myomo make? Myomo (NYSEAMERICAN:MYO) has a market capitalization of $11.42 million and generates $13.86 million in revenue each year. The company earns $-10.37 million in net income (profit) each year or ($1.75) on an earnings per share basis. How many employees does Myomo have? Myomo employs 87 workers across the globe. How can I contact Myomo? Myomo's mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The official website for Myomo is myomo.com. The company can be reached via phone at (617) 996-9058 or via email at ir@myomo.com. This page (NYSEAMERICAN:MYO) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
